Navigation Links
Is prenatal screening for rare diseases like spinal muscular atrophy too costly?
Date:3/8/2010

New York, NY, March 8, 2010 Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. Although the American College of Medical Genetics recommends carrier testing for all couples, the American College of Obstetricians and Gynecologists has issued a recommendation to the contrary, citing lack of information about the costs and benefits of screening for SMA. An article which may shed light on this controversy appears in the March 2010 issue of the American Journal of Obstetrics & Gynecology.

Using a decision analytic model, the authors found that 12,500 women need to be screened to prevent one case of SMA, at a cost of $5 million per case averted. They also determined that at $4.9 million per Quality-Adjusted Life Year (QALY), such screening was not cost-effective. Maternal QALY was used to measure the combined effects of caring for a child who suffers from the disease with resultant premature death and disability.

The cost of the procedures involved, maternal and paternal genetic testing, fetal amniocentesis and genetic testing of fetal cells, were all estimated from data published in the literature. The model assumed that couples with a positive fetal test would elect pregnancy termination. Lifetime costs of caring for an affected child were estimated from costs for similar diseases documented in the medical literature. All costs were adjusted to 2009 dollars using the Consumer Price Index.

The authors found that the cost per case averted was the most influenced by the baseline prevalence of disease in the population screened. For those couples with a higher prevalence, such as those with a family history of disease, screening may be a cost-effective strategy.

Writing in the article, Sarah E. Little, MD, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, and co-authors state that "our estimated cost per added QALY falls far beyond what is usually considered to be cost effective. SMA screening does not approach the cost-effective range ($50-100,000/QALY) until the cost of severe disease is over $7 million or the cost of the mild disease is over $17 million, both of which are more than 20 times the baseline estimates. As such, we feel there is little chance that the basic finding that universal SMA testing is not cost effective would change appreciably with different model inputs."


'/>"/>

Contact: Pamela Poppalardo
ajogmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. MIT: Prenatal arsenic exposure detected in newborns
2. Trainor Lab characterizes gene essential for prenatal development of nervous system
3. Moderate prenatal exposure to alcohol and stress in monkeys can cause touch sensitivity
4. Low sperm count may be associated with prenatal testosterone excess
5. Microarray analysis improves prenatal diagnosis
6. Prenatal meth exposure linked to abnormal brain development
7. How to deliver the news? New advice for doctors diagnosing prenatal Down syndrome
8. Sex-based prenatal brain differences found
9. Good parenting triumphs over prenatal stress
10. UNC study questions FDA genetic-screening guidelines for cancer drug
11. MIT: Micro livers could aid drug screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... RoviSys, a leading ... in Aurora, Ohio, announced the opening of their new office building today. Located ... facility is home to 200 employees focused on providing sales, engineering, and support ...
(Date:12/5/2016)... Research and Markets has announced the ... and Companies" to their offering. ... , , This ... -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are ... based on biomarker. Currently the most important applications of ...
(Date:12/5/2016)... , December 5, 2016 ... Expansion Market, by Products (Consumable, Instruments, Automated Cell ... Medicine and Stem Cell Research, Cancer, and Cell-Based ... Cell Banks) - Global Revenue, Trends, Growth, Share, ... Market Research, the global cell expansion market is ...
(Date:12/5/2016)... , Dec. 5, 2016 NxGen MDx announced today that ... the test in house, we,ve been able to improve customer service through ... patients," says Alan Mack , CEO of NxGen MDx. ... , , A ... volume has led to more job opportunities at the Grand Rapid headquarters. ...
Breaking Biology Technology: